China · Delayed Price · Currency is CNY Guanhao Biotech Statistics
Total Valuation
Guanhao Biotech has a market cap or net worth of CNY 3.10 billion. The enterprise value is 3.00 billion.
| Market Cap | 3.10B |
| Enterprise Value | 3.00B |
Important Dates
The last earnings date was Saturday, August 29, 2026.
| Earnings Date | Aug 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Guanhao Biotech has 265.16 million shares outstanding. The number of shares has decreased by -0.14% in one year.
| Current Share Class | 265.16M |
| Shares Outstanding | 265.16M |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | +8.45% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 7.97% |
| Float | 199.77M |
Valuation Ratios
The trailing PE ratio is 187.53.
| PE Ratio | 187.53 |
| Forward PE | n/a |
| PS Ratio | 8.58 |
| PB Ratio | 6.26 |
| P/TBV Ratio | 6.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 122.03 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 174.83 |
| EV / Sales | 8.31 |
| EV / EBITDA | 62.26 |
| EV / EBIT | 142.62 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.27.
| Current Ratio | 2.06 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 2.80 |
| Debt / FCF | -27.39 |
| Interest Coverage | 10.04 |
Financial Efficiency
Return on equity (ROE) is 1.20% and return on invested capital (ROIC) is 1.58%.
| Return on Equity (ROE) | 1.20% |
| Return on Assets (ROA) | 1.69% |
| Return on Invested Capital (ROIC) | 1.58% |
| Return on Capital Employed (ROCE) | 3.32% |
| Weighted Average Cost of Capital (WACC) | 5.02% |
| Revenue Per Employee | 675,507 |
| Profits Per Employee | 32,115 |
| Employee Count | 535 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Guanhao Biotech has paid 10.31 million in taxes.
| Income Tax | 10.31M |
| Effective Tax Rate | 63.50% |
Stock Price Statistics
The stock price has decreased by -30.15% in the last 52 weeks. The beta is 0.18, so Guanhao Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -30.15% |
| 50-Day Moving Average | 11.56 |
| 200-Day Moving Average | 13.95 |
| Relative Strength Index (RSI) | 49.65 |
| Average Volume (20 Days) | 6,697,693 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guanhao Biotech had revenue of CNY 361.40 million and earned 17.18 million in profits. Earnings per share was 0.06.
| Revenue | 361.40M |
| Gross Profit | 274.66M |
| Operating Income | 21.06M |
| Pretax Income | 16.24M |
| Net Income | 17.18M |
| EBITDA | 41.57M |
| EBIT | 21.06M |
| Earnings Per Share (EPS) | 0.06 |
Balance Sheet
The company has 145.76 million in cash and 135.19 million in debt, with a net cash position of 10.57 million or 0.04 per share.
| Cash & Cash Equivalents | 145.76M |
| Total Debt | 135.19M |
| Net Cash | 10.57M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 495.28M |
| Book Value Per Share | 2.12 |
| Working Capital | 152.74M |
Cash Flow
In the last 12 months, operating cash flow was 25.42 million and capital expenditures -30.36 million, giving a free cash flow of -4.94 million.
| Operating Cash Flow | 25.42M |
| Capital Expenditures | -30.36M |
| Depreciation & Amortization | 20.51M |
| Net Borrowing | 10.88M |
| Free Cash Flow | -4.94M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 76.00%, with operating and profit margins of 5.83% and 4.75%.
| Gross Margin | 76.00% |
| Operating Margin | 5.83% |
| Pretax Margin | 4.49% |
| Profit Margin | 4.75% |
| EBITDA Margin | 11.50% |
| EBIT Margin | 5.83% |
| FCF Margin | n/a |
Dividends & Yields
Guanhao Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.93% |
| Buyback Yield | 0.14% |
| Shareholder Yield | 0.14% |
| Earnings Yield | 0.55% |
| FCF Yield | -0.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Apr 16, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |